Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...

A sensor-augmented pump (SAP ... also known as intensive insulin therapy. The Dexcom G6 and G7 devices are approved by the Food and Drug Administration (FDA) for patients 2 and older. These CGM ...

Adding compatibility for the 15-day CGM may appeal to people with type 1 or type 2 diabetes who use Omnipod insulin pumps and prefer Freestyle Libre CGM sensors. Insulet's Omnipod 5 joins the Tandem t ...

DexCom specializes in continuous glucose monitoring systems, primarily focusing on individuals managing diabetes. Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose ...

had two major product launches with Dexcom One+ and Stelo and submitted our G7 15-day product to the FDA,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “As we enter 2025 ...

She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups. However ...

had two major product launches with Dexcom One+ and Stelo and submitted our G7 15-day product to the FDA.” “As we enter 2025, we look forward to building on these investments as we unlock the ...

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.